Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
AACR & ASCO 2021 – Midyear Review
Videos
Year in Review
Key Abstracts from ASCO 2021 in NSCLC
By
Mark A. Socinski, MD
AACR & ASCO 2021 – Midyear Review
Dr Mark Socinski reviews a broad variety of studies, including the evolving role of
EGFR
inhibitors and immunotherapy in NSCLC, the benefits of immunotherapy plus chemotherapy, and the impact of immune-related adverse events on clinical outcomes in NSCLC.
Read More ›
Year in Review
Atezolizumab versus Best Supportive Care After Adjuvant Chemotherapy for Resected NSCLC (IMpower010)
AACR & ASCO 2021 – Midyear Review
Adjuvant atezolizumab extends disease-free survival after adjuvant chemotherapy compared with best supportive care after adjuvant chemotherapy in patients with resected stage II/IIIA non–small-cell lung cancer (NSCLC).
Read More ›
Year in Review
2021 Midyear Review: Non–Small-Cell Lung Cancer
AACR & ASCO 2021 – Midyear Review
Every year, researchers and clinicians report on exciting advancements in the diagnosis and treatment of cancer. In 2021, despite the COVID-19 pandemic, developments in the management of lung cancer continue to be important and intriguing.
Read More ›
Year in Review
Combination of Nivolumab and Chemotherapy in Nonmetastatic Resectable NSCLC (CheckMate-816)
AACR & ASCO 2021 – Midyear Review
Combining nivolumab with a limited course of chemotherapy in resectable non–small-cell lung cancer (NSCLC) enhances rates of pathologic complete response compared with chemotherapy alone.
Read More ›
Year in Review
Phase 3 Study of Tislelizumab Compared with Docetaxel in Advanced NSCLC (RATIONALE 303)
AACR & ASCO 2021 – Midyear Review
Based on results of the RATIONALE 303 trial, tislelizumab significantly prolonged median overall survival by more than 5 months in patients with advanced non–small-cell lung cancer (NSCLC) compared with docetaxel.
Read More ›
Year in Review
Acquired Resistance Mutations After Treatment of EGFR-Mutated Metastatic NSCLC with Osimertinib plus Savolitinib (TATTON)
AACR & ASCO 2021 – Midyear Review
Resistance to the combination of osimertinib plus savolitinib is predominantly mediated by acquired mutations in either
MET
,
EGFR
, or
KRAS
in patients with
EGFR
-mutated metastatic non–small-cell lung cancer (NSCLC).
Read More ›
Year in Review
Safety Results of Phase 2 Study of Bintrafusp plus Chemotherapy in Advanced NSCLC (INTR@PID LUNG 024)
AACR & ASCO 2021 – Midyear Review
In patients with advanced squamous non–small-cell lung cancer (NSCLC), the combination of bintrafusp alfa and chemotherapy was well tolerated. The most common treatment-related adverse events were anemia, nausea, and pruritus.
Read More ›
Year in Review
Randomized Phase 3 Study of Sintilimab versus Docetaxel in Advanced Squamous NSCLC (ORIENT-3)
AACR & ASCO 2021 – Midyear Review
Compared with docetaxel, sintilimab significantly prolonged median overall survival by more than 3 months in patients with advanced squamous non–small-cell lung cancer (NSCLC).
Read More ›
Year in Review
Phase 1 Trial of VS-6766, a Dual RAF-MEK Inhibitor, and Defactinib, an FAK Inhibitor
AACR & ASCO 2021 – Midyear Review
In patients with non–small-cell lung cancer and
KRAS
G12V mutations who were pretreated with chemotherapy and immunotherapy, the combination of VS-6766 and defactinib is active with an acceptable tolerability profile.
Read More ›
Year in Review
Phase 2 Study of DM-CHOC-PEN in Patients with NSCLC with Central Nervous System Involvement
AACR & ASCO 2021 – Midyear Review
In patients with non–small-cell lung cancer (NSCLC) that involves the central nervous system and who lack genetic rearrangements or tumor targets, DM-CHOC-PEN, a bis-alkylator of DNA, has produced long-term objective responses with manageable toxicities.
Read More ›
Page 1 of 3
1
2
3
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Supported through funding by
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us